STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corp Insider Trading Activity

Twist Bioscience (TWST) CEO executes 10b5-1 plan, exercises options and sells 113,318 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp CEO Emily M. Leproust reported an option exercise and share sale under a previously adopted Rule 10b5-1 trading plan. She exercised 113,318 stock options at $26.66 per share into common stock and on the same date sold 113,318 shares at a weighted average price of $125.1615 per share, with individual sale prices ranging from $125.00 to $125.51. The filing also lists several remaining employee stock option awards with exercise prices between $5.95 and $67.85 and expiration dates from 2025 to 2030.

Positive

  • None.

Negative

  • None.
Insider Leproust Emily M.
Role Chief Executive Officer
Sold 113,318 shs ($14.18M)
Approx. gross sale proceeds $14.18M
Approx. exercise cost $3.02M
Approx. pre-tax spread $11.16M
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F7 113,318 $0.00 $0.00
Exercise Common Stock F1 113,318 $26.66 $3.02M
Sale Common Stock F1, F2 113,318 $125.1615 $14.18M
holding Employee Stock Option (right to buy) F3 -- -- --
holding Employee Stock Option (right to buy) F4 -- -- --
holding Employee Stock Option (right to buy) F5 -- -- --
holding Employee Stock Option (right to buy) F6 -- -- --
Holdings After Transaction: Employee Stock Option (right to buy) — 153,221 shares (Direct); Common Stock — 818,938 shares (Direct)
Footnotes (7)
  1. F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
  2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $125.00 to $125.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. F3. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  4. F4. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  5. F5. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
  6. F6. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  7. F7. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Options Exercised 113,318 shares Employee stock options exercised into common stock on August 10, 2026
Option Exercise Price $26.66 per share Exercise price for 113,318 employee stock options expiring November 18, 2028
Shares Sold 113,318 shares Common stock sold on August 10, 2026 following option exercise
Weighted Average Sale Price $125.1615 per share Weighted average for shares sold, with individual prices from $125.00 to $125.51
Sale Price Range $125.00–$125.51 per share Range of prices at which common shares were sold
10b5-1 Plan Adoption Date May 27, 2025 Date the Rule 10b5-1 trading plan governing these trades was adopted
Other Option Exercise Prices $5.95, $8.82, $23.33, $67.85 Exercise prices of remaining employee stock options expiring 2025–2030
Rule 10b5-1 trading plan regulatory
"The transactions reported ... were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price financial
"Represents the weighted average sales price per share."
performance stock options financial
"Represents performance stock options granted to the reporting person"
vesting financial
"1/48th of the shares subject to the option vest on each monthly anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"

FAQ

What did Twist Bioscience (TWST) CEO Emily Leproust report in this Form 4?
Emily M. Leproust reported exercising 113,318 stock options at $26.66 and selling 113,318 common shares on August 10, 2026. The transactions were made under a Rule 10b5-1 trading plan adopted on May 27, 2025.

How many Twist Bioscience (TWST) shares did the CEO sell and at what price?
She sold 113,318 shares of common stock at a weighted average price of $125.1615 per share. According to the filing, individual sale prices ranged from $125.00 to $125.51 per share, with full price breakdowns available upon request.

What options did the Twist Bioscience (TWST) CEO exercise in this transaction?
She exercised 113,318 employee stock options, each with an exercise price of $26.66 per share, expiring on November 18, 2028. These options converted into an equal number of common shares before being sold the same day.

Were the Twist Bioscience (TWST) CEO’s trades part of a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan previously adopted by the reporting person on May 27, 2025. Such plans pre-schedule trades, reducing the informational value of transaction timing.

Does the Twist Bioscience (TWST) CEO still hold stock options after this sale?
Yes. The filing lists remaining employee stock options with exercise prices of $5.95, $8.82, $23.33, and $67.85 per share, expiring between 2025 and 2030. Reported underlying share amounts for these awards in this filing are shown as zero.

What is the nature of the sale reported for Twist Bioscience (TWST) CEO Emily Leproust?
The sale of 113,318 shares is coded as “S”, indicating a sale in the open market or a private transaction. The filing notes the reported sale price is a weighted average, with more detailed pricing data available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Leproust Emily M.
(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/10/2026M(1)113,318A$26.66932,256D
Common Stock08/10/2026S(1)113,318D$125.1615(2)818,938D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$5.95 (3)09/28/2025Common Stock00D
Employee Stock Option (right to buy)$23.33 (4)10/23/2029Common Stock0131,290D
Employee Stock Option (right to buy)$67.8512/19/202208/31/2030Common Stock064,950(5)D
Employee Stock Option (right to buy)$8.82 (6)09/28/2027Common Stock075,439D
Employee Stock Option (right to buy)$26.6608/10/2026M113,318 (7)11/18/2028Common Stock113,318$0153,221D
Explanation of Responses:
1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
2. Represents the weighted average sales price per share. The shares sold at prices ranging from $125.00 to $125.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
4. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
5. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
6. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
7. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR